New pill could tame blistering skin disease without high steroid doses
NCT ID NCT06696716
First seen Nov 19, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This phase 3 study tests an experimental drug called tirabrutinib for people with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. The trial enrolls 34 adults whose disease is not well controlled by steroids. Participants receive either tirabrutinib or a placebo pill daily, plus a low dose of steroids. The main goal is to see if the drug helps achieve and maintain remission (no or minimal blisters) for at least 8 weeks while keeping steroid use low.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ehime University Hospital
RECRUITINGEhime, Japan
-
Fukushima Medical University Hospital
RECRUITINGFukushima, Japan
-
Gunma University Hospital
RECRUITINGGunma, Japan
-
Hokkaido University Hospital
RECRUITINGHokkaido, Japan
-
Ichinomiya Municipal Hospital
RECRUITINGAichi, Japan
-
Jichi Medical University Hospital
RECRUITINGTochigi, Japan
-
Kagoshima University Hospital
RECRUITINGKagoshima, Japan
-
Kawasaki Medical School Hospital
RECRUITINGOkayama, Japan
-
Keio University Hospital
RECRUITINGTokyo, Japan
-
Kindai university hospital
RECRUITINGOsaka, Japan
-
Kumamoto University Hospital
RECRUITINGKumamoto, Japan
-
Kurume University Hospital
RECRUITINGFukuoka, Japan
-
Nagoya City University Hospital
RECRUITINGAichi, Japan
-
Niigata University Medical & Dental Hospital
RECRUITINGNiigata, Japan
-
Osaka Metropolitan University Hospital
RECRUITINGOsaka, Japan
-
Saitama Medical Center
RECRUITINGSaitama, Japan
-
Shiga University of Medical Science Hospital
RECRUITINGShiga, Japan
-
St.Marianna University School of Medicine Hospital
RECRUITINGKanagawa, Japan
-
Tokai University Hospital
RECRUITINGKanagawa, Japan
-
Tokyo Medical and Dental University Hospital
RECRUITINGTokyo, Japan
-
Tokyo Women'ｓ Medical University Hospital
RECRUITINGTokyo, Japan
-
University Hospital Kyoto Prefectural University of Medicine
RECRUITINGKyoto, Japan
-
University of the Ryukyus Hospital
RECRUITINGOkinawa, Japan
-
Yamagata University Hospital
NOT_YET_RECRUITINGYamagata, Japan
-
Yokohama City University Hospital
RECRUITINGKanagawa, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirabrutinib (a drug taken as a pill that targets a protein involved in immune attacks)
What this could lead to
If successful, this could offer a new treatment option for people with pemphigus that doesn't respond well to steroids, potentially helping control blisters with less steroid use.
What could go wrong
This is a small early-phase 3 trial with only 34 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects like infection or allergic reactions are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.